Hengrui Pharma announced that it has entered into a license agreement with Novo Nordisk (Novo) for HRS-1596, a phase I-ready ...

Link Cell Therapies ("Link"), an oncology cell therapy company utilizing its proprietary logic-gating technology to develop ...

NouvSight001 secures regulatory clearances from the US FDA and China’s NMPA for clinical development in retinitis pigmentosa, ...

It has been evaluated across multiple clinical studies in patients with CLL/SLL who were either previously treated with a ...

The Stockholm Region deployment marks another important milestone in Lunit's expansion across Europe, demonstrating how ...

How this list was built Scope. Every biotech initial public offering with a first trading day between 1 January and 24 ...

Continued investment in Vetter’s broader operational infrastructure accompanies the expansion of its manufacturing capacity.

Collaboration combines Samsung NeuroLogica’s mobile CT expertise with Accuray’s robotic radiosurgery and motion management ...

H. Lundbeck A/S (Lundbeck) announced that it will relocate its US headquarters from Deerfield, Illinois, to Greater Boston, ...

COMPASSION-37 will compare cadonilimab plus chemotherapy against chemotherapy with or without nivolumab as first-line treatment for HER2-negative advanced gastric or gastroesophageal junction ...

Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM) and Incyte (Nasdaq: INCY) announced that the U.S. Food and Drug Administration ...

The candidate is the industry's first gut-restricted pan-TRK inhibitor developed for IBS and IBD, targeting a critical ...